| 本文已被：浏览 1088次 下载 236次 |
码上扫一扫！ |
| 孟鲁司特钠致儿童神经精神系统不良反应文献分析 |
| 雷珍珍1,梁艳1,张莎莎1,任涵1,潘霖1,张章1,刚瑛1,孙晓迪1,战皓1,林志健2,张文想1 |
|
|
| (1. 北京中医药大学东直 门医院,北京 100700;2. 北京中医药大学,北京 102488) |
|
| 摘要: |
| 目的:分析孟鲁司特钠诱发儿童神经精神系统药物不良反应(ADR)的临床特征,为儿科临床安全用药提供参考。 方法: 检索中国知网、万方及 PubMed 数据库,筛选孟鲁司特钠相关神经精神系统 ADR 病例报道,统计分析性别、年龄、ADR 发生时间 及转归等指标。 结果:共纳入 22 篇文献(国内 15 篇、国外 7 篇),涉及 29 例患者,男 20 例(68. 97%),75. 86%因哮喘用药, 72. 41%在用药 2 周内出现 ADR,表现为睡眠障碍、攻击行为、兴奋等,以睡眠障碍(58. 62%)最常见,多数停药后 2 周内缓解。 结论:临床使用孟鲁司特钠时,应加强神经精神症状监测,尤其是男性患儿,并关注患儿潜在自杀风险,出现 ADR 立即停药并就 医,强化监护人用药教育。 |
| 关键词: 孟鲁司特钠 神经精神系统 药物不良反应 儿童 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2025.09.014 |
|
| 基金项目:中国毒理学会临床毒理专项(2020 年度)课题,编号 CST2020CT101。 |
|
| Literature Analysis on Adverse Drug Reactions of Nervous and Psychiatric System Induced by Montelukast Sodium in Children |
| Lei Zhenzhen1 , Liang Yan1 , Zhang Shasha1 , Ren Han1 , Pan Lin1 , Zhang Zhang1 , Gang Ying1 , Sun Xiaodi1 , Zhan Hao1 , Lin Zhijian2 , Zhang Wenxiang1 |
| (1. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China; 2. School of Beijing University of Chinese Medicine, Beijing 102488, China) |
| Abstract: |
| Objective: To analyze the clinical characteristics of adverse drug reactions ( ADR) of nervous and psychiatric system induced by montelukast sodium in children, and provide reference for safe drug use in clinical practice of Pediatrics. Methods: CNKI, Wanfang, and PubMed databases were retrieved to collect ADR cases of nervous and psychiatric system induced by montelukast sodium in children. Statistical analysis was performed on indicators such as gender, age, time of ADR onset, and outcomes. Results: A total of 22 articles (15 domestic and 7 international articles) were enrolled, including 29 patients, 20 cases (68. 97%) were male, 75. 86% were treated for asthma, and 72. 41% developed ADR within 2 weeks of administration. The symptoms were sleep disorders, followed by aggression and agitation, with sleep disorders ( 58. 62%) being the most common. Most symptoms resolved within two weeks of discontinuing the medication. Conclusion: When using montelukast sodium clinically, it is essential to strengthen monitoring of nervous and psychiatric system symptoms, particularly in male patients, and to be vigilant about potential suicide risks in children. If ADR occur, medication should be discontinued immediately, and education on medication for caregiver should be reinforced. |
| Key words: montelukast neuropsychiatric system adverse drug reactions children |
